Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Samsung Biologics : S.Korea approves Moderna's COVID-19 vaccine produced by Samsung Biologics

10/25/2021 | 11:31pm EST

SEOUL, Oct 26 (Reuters) - South Korea granted emergency use approval for Moderna's COVID-19 vaccine produced by South Korean drugmaker Samsung BioLogics, the health ministry said on Tuesday.

Moderna has agreed to distribute 2.44 million doses of the shots produced by Samsung to South Korea after Samsung's COVID-19 vaccine facility on Monday obtained Good Manufacturing Practice (GMP) certification from the drug safety ministry.

Samsung entered into a "fill and finish https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-south-korea-sign-production-deal-mrna-vaccines-2021-05-22 " deal with Moderna in May. This type of contract involves putting vaccines into vials or syringes, sealing them and packaging them up for shipping, but not making the vaccine itself.

The plant has yet to win approval from the U.S. and European regulators to have the shots shipped outside the country, Samsung said.

In May https://www.reuters.com/world/asia-pacific/south-koreas-moon-be-second-leader-second-asian-welcomed-by-biden-2021-05-21, the U.S. President Joe Biden said he and South Korean President Moon Jae-in had agreed on a comprehensive partnership on COVID-19 vaccines.

South Korea said the Moderna shots produced by Samsung will be widely used in the current quarter, including as booster shots for high-risk people. (Reporting by Sangmi Cha; Editing by Lincoln Feast.)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -4.36% 352.43 Delayed Quote.252.74%
SAMSUNG BIOLOGICS CO.,LTD. 0.57% 889000 End-of-day quote.7.63%
All news about SAMSUNG BIOLOGICS CO.,LTD.
11/29Samsung Biologics, GreenLight Biosciences Enter Deal to Produce COVID-19 mRNA Vaccines
MT
11/29South Korean Stocks Fall for Fifth Session Over COVID-19 Variant Omicron Fears; Hyundai..
MT
11/24GreenLight Biosciences and Samsung Biologics Announce Collaboration to Build Capacity f..
CI
11/23South Korea’s Indexes Decline on Profit-Taking; Naver, LG Chem Decline over 2%
MT
11/19South Korean Stocks Break Three-Day Losses to Close Higher; Samsung Biologics Jumps 6% ..
MT
11/15Samsung Biologics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/15Samsung's Lee visits U.S ahead of likely $17 billion chip plant decision-media
RE
11/15S.Korea stocks end 1% higher on chip, biopharma boost, U.S. data in focus
RE
11/08South Korea Stocks Decline as Investors Eye US, China Inflation Data; Biopharma Stocks ..
MT
11/08S.Korean stocks end at near 1-month low as biopharma shares slump
RE
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2021 1 549 B 1,31 B 1,31 B
Net income 2021 440 B 0,37 B 0,37 B
Net Debt 2021 373 B 0,32 B 0,32 B
P/E ratio 2021 134x
Yield 2021 -
Capitalization 58 821 B 49 556 M 49 762 M
EV / Sales 2021 38,2x
EV / Sales 2022 33,3x
Nbr of Employees 2 886
Free-Float 25,0%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | A207940 | KR7207940008 | MarketScreener
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 889 000,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Seok-Woo Jung Independent Director
Sector and Competitors